Founded at the Abramson Cancer Center at the University of Pennsylvania

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

Future Medicine | 2019

Ravi B Parikh; Emily K. Feld; Matthew D. Galsky; Blythe J.S. Adamson; Aaron B. Cohen; Shrujal S. Baxi; Shimon Ben Boursi; John P. Christodouleas; David J. Vaughn; Neal J. Meropol; Ronac Mamtani